Nick Jacobson is a tenure-track assistant professor in the departments of Biomedical Data Science and Psychiatry within the Center for Technology and Behavioral Health in the Geisel School of Medicine at Dartmouth College. He directs the AI and Mental Health: Innovation in Technology Guided Healthcare (AIM HIGH) Laboratory.Dr. Jacobson researches the use of technology to enhance both the assessment and treatment of anxiety and depression. His work has focused on (1) enhancing precision assessment of anxiety and depression using intensive longitudinal data, (2) conducting multimethod assessment utilizing passive sensor data from smartphones and wearable devices, and (3) providing scalable, personalized technology-based treatments utilizing smartphones. He has a strong interest in creating personalized just-in-time adaptive interventions and the quantitative tools that make this work possible. To date, Dr. Jacobson’s smartphone applications which assess and treat anxiety and depression have been downloaded and installed by more than 50,000 people in over 100 countries. Dr. Tobias Kowatsch is Assistant Professor for Digital Health at the University of St. Gallen and the Scientific Director of the Center for Digital Health Interventions, a joint initiative of the Department of Management, Technology and Economics at ETH Zurich and the Institute of Technology Management at the University of St. Gallen. In close collaboration with his interdisciplinary team and research partners, Tobias designs digital health interventions ("digital pills") at the intersection of information systems reserach, comuter science and behavioral medicine. He helped initiate and participates in the on-going development of MobileCoach, an open source platform for ecological momentary assessments, health monitoring and digital health interventions. He is also co-founder of the ETH Zurich and University of St. Gallen spin-off company Pathmate Technologies that creates and delivers digital clinical pathways. Dr. Lisa A. Marsch is the Director of the Dartmouth Center for Technology and Behavioral Health, a designated “Center of Excellence” supported by the National Institute on Drug Abuse at the National Institutes of Health. She is also the Director of the Northeast Node of the National Drug Abuse Clinical Trials Network based out of Dartmouth and the Andrew G. Wallace Professor within the Department of Psychiatry at the Geisel School of Medicine at Dartmouth College. And, she leads a national “Science of Behavior Change” initiative supported by the National Institutes of Health with partners at Dartmouth, Stanford, Arizona State University, Drexel, and MIT.In addition to directing this national Center, Dr. Marsch has personally been Principal Investigator on 35 grants, largely from the National Institutes of Health. She has led the development, evaluation and implementation of technology-based therapeutic tools for addiction treatment, HIV prevention, mental health, chronic pain management, substance abuse prevention, smoking cessation, and binge eating disorder. Her work in technology and addiction treatment has been particularly pioneering, as she is widely recognized as having led the development of one of the most widely tested and evidence-based mobile intervention for addiction treatment.Dr. Marsch publishes extensively and is a regular keynote speaker at national and international scientific meetings (including invited presentations at the White House, Congressional briefings, the World Bank, and for the US Surgeon General). She has served as a consultant to the Department of Mental Health and Substance Abuse at the World Health Organization. She serves on the National Advisory Council to the National Institute on Drug Abuse at the National Institutes of Health. And, she serves on the Health Information Technology Policy Committee on Advanced Health Models and Meaningful Use for the U.S. Office of the National Coordinator.She also led the development of a seminal book from Oxford University Press on the state of the science of leveraging technologies in transforming behavioral health care.

• Section A. Introduction and Evidence Base1. Need for a Paradigm Shift: Gaps and Failures in Traditional Mental Health and Addiction Treatments2. Digital Therapeutics: A New Class of Tools for Old Problems3. State of the Science of Internet-Based Programs for Direct-to-Consumer Standalone Care for Mental Health and Addiction4. State of the Science of Mental Health and Addiction Treatment Apps for Direct-to-Consumer Standalone Care (Second Wave of Scalable Digital Therapeutics)5. Blending Digital Therapeutics with Traditional Treatments within the Healthcare SystemSection B. The New Frontier6. Using Advances in Technology to Identify Digital Biomarkers to Improve Passive Patient Monitoring7. Receptivity of Mobile Health Interventions8. Analytics for Adapting Interventions to Context Targeting Vulnerability and Receptivity9. Digital Therapeutic Alliance10. The First Wave of Conversational Agents: Chatbots Embedded within Smartphones and the Internet11. The Second Wave of Conversational Agents: Voice Assistants within Everyday Objects and the Internet of ThingsSection C. Import Considerations12. Cultural Adaptations of Digital Therapeutics13. Implementation, Business Models, and Regulation14. Lessons Learned and Potential Pitfalls15. Privacy and Security16. Ethical Considerations of Digital Therapeutics17. Design Considerations for Preparation, Optimization, Evaluation and Maintaining Digital Therapeutics18. Futuristic Vision 10-20 Years Out

Select Guide Rating